title: Linezolid is superior to vancomycin in experimental pneumonia caused by Superantigen-Producing staphylococcus aureus in HLA class II transgenic mice.
abstract: Superantigens (SAg), the potent activators of the immune system, are important determinants of Staphylococcus aureus virulence and pathogenicity. Superior response to SAg in human leukocyte antigen (HLA)-DR3 transgenic mice rendered them more susceptible than C57BL/6 mice to pneumonia caused by SAg-producing strains of S. aureus. Linezolid, a bacterial protein synthesis inhibitor, was superior to vancomycin in inhibiting SAg production by S. aureus in vitro and conferred greater protection from pneumonia caused by SAg-producing staphylococci.
authors: Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
authors: Melissa J
authors: MJ
authors: Karau
authors: Ashenafi Y
authors: AY
authors: Tilahun
authors: Suzannah M
authors: SM
authors: Schmidt
authors: Chad R
authors: CR
authors: Clark
authors: Robin
authors: R
authors: Patel
authors: Govindarajan
authors: G
authors: Rajagopalan
mesh_terms: D000081:Acetamides / Q000627:therapeutic use*; D000818:Animals; D000069349:Linezolid; D051379:Mice; D008807:Mice, Inbred BALB C; D008822:Mice, Transgenic; D023303:Oxazolidinones / Q000627:therapeutic use*; D018410:Pneumonia, Bacterial / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000472:pathogenicity*; D018089:Superantigens / Q000378:metabolism*; D014640:Vancomycin / Q000627:therapeutic use*
chemical_list: D000081:Acetamides; D023303:Oxazolidinones; D018089:Superantigens; D014640:Vancomycin; D000069349:Linezolid